Cochrane · systematic review · CD011451
Acetyl‐L‐carnitine for patients with hepatic encephalopathy
Martí‐Carvajal, AJ, Gluud, C, Arevalo‐Rodriguez, I, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 42.9%Very low 3 · 42.9%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Acetyl‐L‐carnitine compared with placebo for patients with hepatic encephalopathy
Population: patients with covert or overt hepatic encephalopathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Acetyl‐L‐carnitine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Quality of life (general health at 90 days) SF‐36 scale Scale from 0 to 100 Acetyl‐L‐carnitine vs placebo | no estimate extracted | 1 study · 67 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Acetyl‐L‐carnitine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Fatigue Mental fatigue in moderate‐grade hepatic encephalopathy Wessely and Powell test Scale from 0 to 10 Acetyl‐L‐carnitine vs placebo | no estimate extracted | 1 study · 121 participants | Very low Downgraded: risk of bias, imprecision |
Non‐serious adverse events Acetyl‐L‐carnitine vs placebo | RR 2.51 [0.68, 9.22] | 2 studies · 246 participants | Very low Downgraded: risk of bias, imprecision |
Days of hospitalisation Acetyl‐L‐carnitine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Blood ammonium levels Acetyl‐L‐carnitine vs placebo | no estimate extracted | 5 studies · 387 participants | Low Downgraded: risk of bias, inconsistency |